Safety of megadose meropenem in the empirical treatment of nosocomial sepsis: a pilot randomized clinical trial-Reference-Cited by-同舟云学术

Safety of megadose meropenem in the empirical treatment of nosocomial sepsis: a pilot randomized clinical trial

Published:2023-04 Issue:6 Volume:18 Page:335-342
ISSN:1746-0913
Container-title:Future Microbiology
language:en
Short-container-title:Future Microbiology

Author:

Salehi Mohammadreza¹^ORCID,Rezazade-Moayed Farah¹,Khalili Hossein²^ORCID,Hemati Homa²,Aghdami Nasser¹³,Dashtkoohi Mohadese⁴^ORCID,Dashtkoohi Mohammad⁴,Beig-Mohammadi Mohammad-Taghi⁵,Ramezani Masoud⁵,Hajiabdolbaghi Mahboobeh¹,Fattah-Ghazi Samrand⁵

Affiliation:

1. Research Center for Antibiotic Stewardship and Antimicrobial Resistance, Imam Khomeini Hospital Complex, Department of Infectious Diseases, Tehran University of Medical Sciences, Tehran, Iran

2. Research Center for Antibiotic Stewardship and Antimicrobial Resistance, Imam Khomeini Hospital Complex, Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

3. Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology & Technology, Academic Center for Education, Culture & Research, Tehran, Iran

4. Students' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran

5. Critical Care Department, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran

Abstract

Objective: To evaluate the safety of megadose meropenem as empirical treatment of nosocomial sepsis. Materials & methods: Critically ill patients diagnosed with sepsis received either high-dose (2 g every 8 h) or megadose (4 g every 8 h) meropenem as an intravenous infusion over 3 h. Results: A total of 23 patients with nosocomial sepsis were eligible and included in the megadose (n = 11) or high-dose (n = 12) group. No treatment-related adverse events were observed during a 14-day follow-up. Clinical response was also comparable between the groups. Conclusion: Megadose meropenem may be considered for empirical treatment of nosocomial sepsis without serious concern regarding its safety.

Publisher

Future Medicine Ltd

Subject

Microbiology (medical),Microbiology

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fmb-2022-0170

Reference38 articles.

1. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)

2. Comparison of two empirical prolonged infusion dosing regimens for meropenem in patients with septic shock: A two-center pilot study

3. Sepsis: Evidence-based pathogenesis and treatment

4. Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis. A Meta-analysis of Individual Patient Data from Randomized Trials